AxoGen (AXGN) Competitors $17.60 +0.40 (+2.33%) Closing price 04:00 PM EasternExtended Trading$17.57 -0.03 (-0.17%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AXGN vs. SLNO, WRBY, INSP, LQDA, LMAT, PRCT, AORT, EYE, ENOV, and CNMDShould you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Soleno Therapeutics (SLNO), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. AxoGen vs. Its Competitors Soleno Therapeutics Warby Parker Inspire Medical Systems Liquidia Technologies LeMaitre Vascular PROCEPT BioRobotics Artivion National Vision Enovis CONMED Soleno Therapeutics (NASDAQ:SLNO) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has more volatility & risk, SLNO or AXGN? Soleno Therapeutics has a beta of -2.71, indicating that its share price is 371% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Does the media prefer SLNO or AXGN? In the previous week, Soleno Therapeutics had 6 more articles in the media than AxoGen. MarketBeat recorded 12 mentions for Soleno Therapeutics and 6 mentions for AxoGen. AxoGen's average media sentiment score of 0.68 beat Soleno Therapeutics' score of 0.43 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, SLNO or AXGN? AxoGen has higher revenue and earnings than Soleno Therapeutics. AxoGen is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-13.67AxoGen$187.34M4.32-$9.96M-$0.10-176.00 Do analysts prefer SLNO or AXGN? Soleno Therapeutics presently has a consensus price target of $115.09, suggesting a potential upside of 103.41%. AxoGen has a consensus price target of $26.00, suggesting a potential upside of 47.73%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Soleno Therapeutics is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08AxoGen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLNO or AXGN more profitable? Soleno Therapeutics has a net margin of 0.00% compared to AxoGen's net margin of -2.29%. AxoGen's return on equity of -4.43% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% AxoGen -2.29%-4.43%-2.34% Do insiders & institutionals hold more shares of SLNO or AXGN? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 2.8% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummarySoleno Therapeutics beats AxoGen on 9 of the 16 factors compared between the two stocks. Get AxoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXGN vs. The Competition Export to ExcelMetricAxoGenMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$791.42M$6.76B$5.80B$10.46BDividend YieldN/A1.21%5.61%4.57%P/E Ratio-175.9826.38348.5626.86Price / Sales4.32197.16549.90125.65Price / CashN/A22.1426.0131.15Price / Book7.465.0615.536.50Net Income-$9.96M$178.07M$3.29B$271.25M7 Day Performance7.51%1.53%200.87%3.69%1 Month Performance8.24%6.98%184.38%8.07%1 Year Performance25.00%19.02%325.51%29.65% AxoGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXGNAxoGen2.8602 of 5 stars$17.60+2.3%$26.00+47.7%+22.2%$791.42M$187.34M-175.98450SLNOSoleno Therapeutics4.4274 of 5 stars$51.17-4.6%$115.09+124.9%+6.1%$2.85BN/A-12.3630WRBYWarby Parker1.4502 of 5 stars$26.37-1.4%$24.06-8.8%+99.4%$2.81B$771.32M-376.723,780Insider TradeINSPInspire Medical Systems4.8452 of 5 stars$80.90+1.1%$164.50+103.3%-62.5%$2.37B$802.80M46.761,246Analyst ForecastGap DownLQDALiquidia Technologies3.94 of 5 stars$26.77+3.0%$32.11+20.0%+139.0%$2.24B$14M-15.7550LMATLeMaitre Vascular3.0654 of 5 stars$92.37+0.1%$97.60+5.7%+2.5%$2.09B$219.86M44.84490Positive NewsPRCTPROCEPT BioRobotics2.7618 of 5 stars$38.00+2.3%$73.22+92.7%-56.0%$2.07B$224.50M-24.52430Positive NewsAORTArtivion2.5653 of 5 stars$39.74-2.4%$40.63+2.2%+61.0%$1.92B$388.54M-94.621,600Positive NewsEYENational Vision2.5552 of 5 stars$23.61+2.7%$24.73+4.7%+154.4%$1.82B$1.82B-131.1713,411ENOVEnovis4.3531 of 5 stars$32.35+2.0%$51.00+57.7%-25.9%$1.81B$2.11B-2.277,367Positive NewsCNMDCONMED4.4434 of 5 stars$51.76-2.1%$59.80+15.5%-33.5%$1.64B$1.31B14.663,900 Related Companies and Tools Related Companies SLNO Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives LMAT Alternatives PRCT Alternatives AORT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXGN) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXGN Stock Alerts